Madrigal Pharmaceuticals, Inc.

NasdaqGS:MDGL Stock Report

Market Cap: US$12.3b

Madrigal Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:MDGL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Sep 26SellUS$3,407,397William SiboldIndividual6,362US$542.55
17 Aug 26SellUS$341,940Shannon KelleyIndividual664US$514.97
18 May 26SellUS$435,420David SoergelIndividual844US$515.90
06 Mar 26SellUS$279,033Mardi DierIndividual646US$431.94
06 Mar 26SellUS$718,316William SiboldIndividual1,663US$431.94
06 Mar 26SellUS$212,083Rebecca TaubIndividual491US$431.94
06 Mar 26SellUS$180,983Carole HuntsmanIndividual419US$431.94
06 Mar 26SellUS$155,498Shannon KelleyIndividual360US$431.94
02 Mar 26SellUS$505,389Mardi DierIndividual1,183US$427.21
26 Jan 26SellUS$167,423Carole HuntsmanIndividual340US$492.42
26 Jan 26SellUS$318,596Rebecca TaubIndividual647US$492.42
26 Jan 26SellUS$776,546William SiboldIndividual1,577US$492.42
20 Jan 26SellUS$1,098,343Rebecca TaubIndividual2,238US$490.77
20 Jan 26SellUS$129,073Shannon KelleyIndividual263US$490.77
21 Nov 25SellUS$1,082,986Carole HuntsmanIndividual1,958US$564.57

Insider Trading Volume

Insider Buying: MDGL insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of MDGL?
Owner TypeNumber of SharesOwnership Percentage
State or Government7,6300.0295%
Private Companies850,7033.28%
Individual Insiders1,212,1694.68%
Hedge Funds7,310,17128.2%
Institutions16,523,64763.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 81.21% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.28%
Baker Bros. Advisors LP
2,143,131US$1.1b0.07%5.54%
8.63%
RTW Investments, LP
1,993,687US$1.1b0%9.17%
8.38%
Janus Henderson Group Ltd.
1,936,099US$1.0b-4.09%0.35%
7.94%
Avoro Capital Advisors LLC
1,833,333US$979.9m0.83%8.9%
5.8%
Paulson & Co. Inc.
1,340,020US$716.2m-3.75%13.69%
5.2%
BlackRock, Inc.
1,200,770US$641.8m-23%0.01%
4.14%
Vanguard Capital Management, LLC
957,251US$511.6m0.21%0.01%
3.57%
Wellington Management Group LLP
825,714US$441.3m18.8%0.07%
3.38%
Vanguard Portfolio Management, LLC
781,731US$417.8m-7.06%0.02%
2.84%
SQN, LLC
655,540US$350.4m0%no data
2.28%
State Street Investment Management
527,057US$281.7m-13.5%0.01%
2.2%
Citadel Advisors LLC
507,233US$271.1m11.8%0.16%
1.91%
Rebecca Taub
441,033US$235.7m0%no data
1.88%
UBS Asset Management AG
434,111US$232.0m207%0.02%
1.62%
Geode Capital Management, LLC
374,880US$200.4m-17.8%0.01%
1.59%
Frederick Craves
368,004US$196.7m0%no data
1.54%
FMR LLC
356,034US$190.3m-30.4%0.01%
1.46%
William Blair Investment Management, LLC
337,834US$180.6m-4.63%0.23%
1.25%
Armistice Capital LLC
288,000US$153.9m8.85%3.96%
1.22%
Lord, Abbett & Co. LLC
281,500US$150.5m16%0.43%
1.22%
Invesco Ltd.
281,129US$150.3m-9.82%0.03%
1.06%
Polar Capital Holdings Plc
244,274US$130.6m-15.6%0.27%
1%
Columbia Management Investment Advisers, LLC
231,205US$123.6m135%0.02%
0.93%
Norges Bank Investment Management
213,886US$114.3m8.91%0.01%
0.91%
Artisan Partners Limited Partnership
210,205US$112.4m14.5%0.08%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 04:11
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Madrigal Pharmaceuticals, Inc. is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Matthew LuchiniBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research